Inactive Instrument

Avisa Diagnostics Inc. Canadian Securities Exchange

Equities

MKU.H

CA05380J1075

Biotechnology & Medical Research

Avisa Pharma, Inc. announced that it has received $3.573729 million in funding

June 27, 2018

On June 28, 2018, Avisa Pharma, Inc. closed the transaction. On the same date, the company amended the terms of the transaction. The company received $129,000 in the final tranche. The company received $3,573,729 from 51 investors in the transaction.

Latest news about Avisa Diagnostics Inc.

Chart Avisa Diagnostics Inc.

Duration

Period

More charts

Company Profile

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via its own delivery systems. Its ABT portfolio includes Post-Covid-19 Bronchiectasis, Develo, Ventilator-Associated Pneumonia (VAP), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired, Pneumonia (CAP), Cystic Fibrosis, Tuberculosis, Aspergillus Fungus and Clostridium Difficile (C. diff).

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research